share_log
Reuters ·  May 6 08:00
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3361, a Cab-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment